For cholera and LT-producing ETEC diarrhea
HELP PREVENT AND PROTECT WITH DUKORAL®1
To help reduce the chances of cholera and LT-producing ETEC diarrhea while travelling
DUKORAL® [Oral, Inactivated Cholera and LT-producing ETEC Diarrhea Vaccine] is indicated for the prevention of and protection against cholera and diarrhea caused by heat-labile toxin producing enterotoxigenic Escherichia coli (LT-producing ETEC) in adults and children from 2 years of age.1
Your patients are ready to travel again. Consider DUKORAL® during the travel season.
DUKORAL® is a drinkable vaccine that protects against BOTH cholera and diarrhea caused by LT-producing ETEC.1
Clinical significance unknown.
DUKORAL® is a CDHF certified product2
Keeping your patients informed about the risk factors, causes, and preventative measures available for cholera and LT-producing ETEC diarrhea during travel is important.
Your pre-travel health advice can help your patients prevent and protect against cholera and LT-producing ETEC diarrhea during their travels.
Explore the site to learn more about DUKORAL®!
LT-PRODUCING ETEC
CHOLERA
ABOUT DUKORAL®
Learn about the vaccine, its efficacy profile, dosing, administration and get access to useful resources for your patients.
Safety information1
Contraindications:
- Hypersensitivity to any component of DUKORAL® or its container, to formaldehyde, or an anaphylactic or other hypersensitivity reaction to a previous dose of DUKORAL®.
- Immunization with DUKORAL® should be deferred in the presence of acute gastrointestinal illness or acute febrile illness.
Most serious warnings and precautions:
- Administration: DO NOT ADMINISTER THIS VACCINE PARENTERALLY. THIS VACCINE MUST BE TAKEN ORALLY (BY MOUTH) AFTER MIXING IT WITH THE BUFFER SOLUTION.
- Gastrointestinal: As with any vaccine, immunization with DUKORAL® may not protect 100% of susceptible persons. There are multiple etiologies responsible for acute diarrhea in travellers. DUKORAL® can only confer protection against cholera and LT-producing ETEC. Therefore it should not replace standard preventive hygiene measures. Travellers should use care in the choice of food and water supply and use good hygienic measures. Rehydration measures must be taken in case of diarrhea.
- Immune: Immunocompromised persons (whether from disease or treatment) may not obtain the expected immune response. If possible, consideration should be given to delaying vaccination until after the completion of any immunosuppressive treatment. DUKORAL® can be given to HIV-infected persons. Limited data are available on immunogenicity and safety of the vaccine. Vaccine protective efficacy has not been studied among HIV-infected persons.
- DUKORAL® confers protection specific to Vibrio cholerae serogroup O1. DUKORAL® has not been demonstrated to protect against cholera caused by V. cholerae serogroup O139 or other species of Vibrio.
- DUKORAL® confers protection specific to LT-producing ETEC (either LT alone or both LT and heat-stable enterotoxin (ST) together). DUKORAL® has not been demonstrated to protect against ETEC strains that do not produce LT.
Other relevant warnings and precautions:
- Before administration, take all appropriate precautions to prevent adverse reactions. This includes a review of the patient’s history concerning possible hypersensitivity to the vaccine or similar vaccines, previous immunization history, the presence of any contraindications to immunization and current health status.
- DUKORAL® contains approximately 1.2 g sodium per dose, which should be taken into consideration by patients on a controlled sodium diet.
- Before administration of the vaccine, healthcare providers should inform the patient, parent or guardian of the benefits and risks of immunization, inquire about the recent health status of the patient and comply with any local requirements regarding information to be provided to the patient before immunization. Patients should be advised on the importance of taking the vaccine correctly (mixed with buffer and at dosing intervals of at least one week) and completing the immunization series at least one week before departure to achieve optimal protection.
- Formaldehyde is used during the manufacturing process and trace amounts may be present in the final product. Caution should be taken in subjects with known hypersensitivity to formaldehyde.
- There are only very limited data on protective efficacy of the vaccine in the geriatric population. However, this population can be expected to be at risk of more severe complications of disease if infected by cholera or LT-producing ETEC and therefore may obtain greater benefit from vaccination.
- Populations with increased susceptibility to cholera and LT-producing ETEC diarrhea and who are at higher risk for more severe disease include persons with achlorhydia, gastrectomy, history of repeated severe diarrhea, young children >2 years, immunosuppressed due to HIV infection with depressed CD4 count or other immunodeficiency states.
- Administration of DUKORAL® to pregnant women may be considered after careful evaluation of the benefits and risks.
For more information:
Please consult the DUKORAL® Product Monograph at https://pdf.hres.ca/dpd_pm/00071386.PDF for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.
The Product Monograph is also available by calling 1-855-356-0831.
The drug identification number (DIN) for DUKORAL® is 02247208.
